Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ING Groep NV (ING) vs Invesco Ltd. (IVZ) Price & Performance

ING Groep NVTrade
Invesco Ltd.Trade

Price performance (Past 24H)

Key statistics

ING Groep NV vs Invesco Ltd. — how do they compare? ING Groep NV trades at $33.25 (market cap $93.76B), while Invesco Ltd. trades at $29.7 (market cap $13.28B). The key difference: ING Groep NV is far larger — about 7.1× Invesco Ltd.'s market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and Invesco Ltd. for 77 Days on average.

INGIVZ
Market Cap
$93.76B$13.28B
Volume
4,620,2203,698,033
Sector
FinancialsFinancials
52-Week High
$37.27$33.31
52-Week Low
$23.66$22.44
Typical Hold Time
93 Days77 Days
Enterprise Value
$236.48B$23.45B
Dividend Yield
3.95%2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ING Groep NV

ING stock trades at $33.28, down 1.89% today, with bearish technical signals despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains a 28.34% net income margin, and analysts show strong support with 11 buy ratings versus no sell ratings. Recent news highlights management's raised ROE target above 16% for 2027 and strategic focus on organic growth.

The investment case balances solid profitability and analyst optimism against technical weakness and cash flow challenges. Upside potential exists from earnings momentum and strategic initiatives, while risks include persistent negative operating cash flows and regulatory scrutiny in international markets.

Invesco Ltd.

Invesco (IVZ) trades at $29.66, down 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. Fundamentally, the company reported negative net income of -$282 million in 2025 despite $6.38 billion revenue, though operating cash flow remains strong at $1.53 billion. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results expected October 27.

The outlook remains cautious with analyst consensus at Buy (43%) and Hold (57%), targeting $33.71. Key risks include profitability challenges and market volatility, while opportunities lie in AUM growth and dividend yield. The stock trades near the lower end of analyst targets, suggesting limited downside but requiring improved earnings for sustained recovery.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ING
100% Buy0% Sell
Avg holding period · 93 Days
IVZ

No sentiment data available yet.

Top news

Latest headlines on both assets

About ING Groep NV

The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.

Read more on ING →

About Invesco Ltd.

Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).

Read more on IVZ →